Based on this YouTube video's total view count of 485 views and industry-standard rates, the estimated total earning is $0 - $1 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Life Sciences Virtual Investor Forum - Amplia Therapeutics Limited (ASX: ATX) with 485 views, 0 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

This video is part of the ‪@OTCMarketsGroup Life Sciences Virtual Investor Forum Hosted by Virtual Investor Conferences, a ‪ @b2idigital Featured Conference, held on March 11th & 12th, 2026. @ampliatherapeuticslimited6227 (ASX: ATX) is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. The first of these drugs, narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). Orphan Drug Designations for pancreatic cancer and IPF have been granted by the US FDA. The FDA has also cleared Amplia’s investigational new drug (IND) submission to allow for a clinical trial in pancreatic cancer in the US. Amplia Therapeutics Limited (ASX: ATX) is second pipeline drug, AMP886, inhibits FAK and also inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is currently being evaluated in preclinical models of cancer. Amplia Therapeutics Limited (ASX: ATX) is pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and drug discovery researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation. Amplia Therapeutics Limited (ASX: ATX) is Board and Management team includes highly experienced and well-credentialed life-science executives who have extensive international experience in drug development, pharmaceuticals, and life-sciences deal-making. Watch the full Amplia Therapeutics Limited (ASX: ATX) presentation and request meetings with management at: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5266562/amplia-therapeutics-ltd-otcqb-innmf-asx-atx?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC Any questions or need assistance setting up meetings, contact Joseph Azizo, Capital Markets Associate at B2i Digital: [email protected]

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.